Range Low Price High Price Comment
30 days $2.30 $3.29 Monday, 29th Apr 2024 ABUS stock ended at $2.78. This is 1.83% more than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 2.19% from a day low at $2.74 to a day high of $2.80.
90 days $2.27 $3.29
52 weeks $1.69 $3.29

Historical Arbutus Biopharma Corporation prices

Date Open High Low Close Volume
Jan 29, 2016 $3.14 $3.14 $3.14 $3.14 443 600
Jan 28, 2016 $3.25 $3.25 $3.25 $3.25 407 500
Jan 27, 2016 $3.43 $3.43 $3.43 $3.43 235 300
Jan 26, 2016 $3.58 $3.58 $3.58 $3.58 160 400
Jan 25, 2016 $3.64 $3.64 $3.64 $3.64 190 100
Jan 22, 2016 $3.59 $3.59 $3.59 $3.59 305 100
Jan 21, 2016 $3.52 $3.52 $3.52 $3.52 357 800
Jan 20, 2016 $3.51 $3.51 $3.51 $3.51 360 800
Jan 19, 2016 $3.48 $3.48 $3.48 $3.48 323 300
Jan 15, 2016 $3.70 $3.70 $3.70 $3.70 390 800
Jan 14, 2016 $3.81 $3.81 $3.81 $3.81 309 700
Jan 13, 2016 $3.72 $3.72 $3.72 $3.72 484 800
Jan 12, 2016 $3.81 $3.81 $3.81 $3.81 354 000
Jan 11, 2016 $3.84 $3.84 $3.84 $3.84 449 900
Jan 08, 2016 $4.02 $4.02 $4.02 $4.02 346 200
Jan 07, 2016 $4.10 $4.10 $4.10 $4.10 469 200
Jan 06, 2016 $4.30 $4.30 $4.30 $4.30 288 800
Jan 05, 2016 $4.51 $4.51 $4.51 $4.51 207 200
Click to get the best stock tips daily for free!

About Arbutus Biopharma Corporation

Arbutus Biopharma Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT